Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus target price of $18.00 for the company and are predicting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned Eton Pharmaceuticals an industry rank of 51 out of 256 based on the ratings given to related companies.
Separately, HC Wainwright reiterated a “buy” rating on shares of Interpace Diagnostics Group in a research report on Friday, June 21st.
Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.42) EPS for the quarter. The company had revenue of $0.50 million during the quarter. Equities research analysts expect that Eton Pharmaceuticals will post -1.41 EPS for the current fiscal year.
In related news, CEO Sean Brynjelsen purchased 10,000 shares of Eton Pharmaceuticals stock in a transaction on Tuesday, May 21st. The stock was acquired at an average price of $7.93 per share, for a total transaction of $79,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 13.46% of the stock is currently owned by corporate insiders.
A hedge fund recently bought a new stake in Eton Pharmaceuticals stock. Opaleye Management Inc. purchased a new position in Eton Pharmaceuticals Inc (NASDAQ:ETON) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 523,000 shares of the company’s stock, valued at approximately $3,200,000. Eton Pharmaceuticals makes up 1.2% of Opaleye Management Inc.’s holdings, making the stock its 26th biggest position. Opaleye Management Inc. owned approximately 2.97% of Eton Pharmaceuticals as of its most recent SEC filing. 8.52% of the stock is currently owned by hedge funds and other institutional investors.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.